DERM
Journey Medical Corporation (NASDAQ)
Healthcare — Drug Manufacturers - Specialty & Generic
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Price History
Fundamentals
| Market Cap | $193.84M |
| P/E Ratio (TTM) | - |
| Forward P/E | -117.33 |
| EPS (TTM) | $-0.37 |
| Dividend Yield | - |
| Profit Margin | -14.82% |
| Revenue Growth | 21.50% |
| ROE | -36.62% |
| Debt/Equity | 82.60 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $13.50 |
| Analysts | 4 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 65.4 |
| Beta | 1.10 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $9.56 |
| 52-Week Low | $4.31 |
| 50-Day Avg | $5.89 |
| 200-Day Avg | $7.11 |
| Avg Volume | 275.1K |
| Volume | 155.6K |
Performance Analysis
BULLISHDERM shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:05 UTC
Back to Screener Export Report